{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:43Z","timestamp":1788307243982,"version":"build-2803163510"},"reference-count":261,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Four vaccines have been authorized by the European Medicines Agency (EMA): viral vector-based vaccines (AstraZeneca; AZD1222 and Johnson &amp; Johnson; Ad26.COV2. and 2 mRNA-based vaccines (Pfizer\/BioNTech; BNT162b2 and Moderna; mRNA-1273). Adverse events (AEs) related to vaccination have been described in the literature. The main aim of the dermatological practice was to avoid the diffusion of COVID-19, allowing the continuity of care for patients. Objective: The aim of this review article is to investigate current literature regarding cutaneous reactions following COVID-19 vaccination, mainly inflammatory dermatological diseases. Materials and methods: Investigated manuscripts included metanalyses, reviews, letters to the editor, real-life studies, case series, and reports. Results: We selected a total of 234 articles involving more than 550 patients. We have divided the results section into various sub-sections to ensure greater understanding for readers. Conclusions: Clinicians should keep in mind the possibility of new onsets or the worsening of several dermatoses following vaccination in order to promptly recognize and treat these AEs. Certainly, vaccination should not be discouraged.<\/jats:p>","DOI":"10.3390\/v15071423","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T02:05:02Z","timestamp":1687745102000},"page":"1423","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Battista","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Villani","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-3-030-85113-2_2","article-title":"Outbreak of COVID-19: A Detailed Overview and Its Consequences","volume":"1353","author":"Shivalkar","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/ijd.15809","article-title":"Scabies outbreak during COVID-19: An Italian experience","volume":"60","author":"Potestio","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e15000","DOI":"10.1111\/ijcp.15000","article-title":"Teledermatology in the time of COVID-19","volume":"75","author":"Ibrahim","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/jocd.14938","article-title":"Teledermatology: A useful tool also after COVID-19 era?","volume":"21","author":"Megna","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13671-021-00333-6","article-title":"International Teledermatology Review","volume":"10","author":"McKoy","year":"2021","journal-title":"Curr. Dermatol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Marasca, C., Annunziata, M.C., Camela, E., Di Guida, A., Fornaro, L., Megna, M., Napolitano, M., Patruno, C., Potestio, L., and Fabbrocini, G. (2022). Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061511"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"663074","DOI":"10.3389\/fimmu.2021.663074","article-title":"Addressing Parental Vaccine Hesitancy and Other Barriers to Child-hood\/Adolescent Vaccination Uptake During the Coronavirus (COVID-19) Pandemic","volume":"12","author":"Olusanya","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hudson, A., and Montelpare, W.J. (2021). Predictors of Vaccine Hesitancy: Implications for COVID-19 Public Health Messaging. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18158054"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"714170","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_10","unstructured":"European Medicines Agency (2023, May 18). COVID-19 Vaccines: Authorised. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-COVID-19\/treatments-vaccines\/vaccines-COVID-19\/COVID-19-vaccines-authorised."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2147\/CCID.S388245","article-title":"Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature","volume":"15","author":"Martora","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_12","unstructured":"(2020, June 08). COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_13","unstructured":"(2023, May 18). COVID-19 Vaccine Tracker and Landscape. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-COVID-19-candidate-vaccines."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events after COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jocd.15533","article-title":"Cutaneous reactions following COVID-19 vaccination: The evidence says \u201cless fear\u201d","volume":"22","author":"Potestio","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_16","first-page":"e43","article-title":"Skin reaction after SARS-CoV-2 vaccines Reply to \u2018cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: A real-life multicentre experience\u2019","volume":"37","author":"Martora","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jocd.15414","article-title":"COVID-19 vaccination and inflammatory skin diseases","volume":"22","author":"Martora","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.2147\/CCID.S377029","article-title":"The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40257-022-00721-z","article-title":"New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review","volume":"23","author":"Wu","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/ced.15336","article-title":"The impact of COVID-19 infection on patients with psoriasis treated with biologics: An Italian experience","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e15102","DOI":"10.1111\/dth.15102","article-title":"Onset of vitiligo in a psoriasis patient on ixekizumab","volume":"34","author":"Marasca","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e15872","DOI":"10.1111\/dth.15872","article-title":"Generalized vitiligo in a psoriatic patient treated with ixekizumab","volume":"35","author":"Pathmarajah","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: State of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14712598.2022.2089020","article-title":"Treating psoriasis in the elderly: Biologics and small molecules","volume":"22","author":"Megna","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14740338.2023.2173170","article-title":"Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: Focus on pediatric patients","volume":"22","author":"Megna","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Megna, M., Ruggiero, A., Battista, T., Marano, L., Cacciapuoti, S., and Potestio, L. (2023). Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093233"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e15667","DOI":"10.1111\/dth.15667","article-title":"Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting","volume":"35","author":"Megna","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e15941","DOI":"10.1111\/dth.15941","article-title":"Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14740338.2022.2160447","article-title":"Drug safety evaluation of tildrakizumab for psoriasis: A review of the current knowledge","volume":"21","author":"Ruggiero","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14740338.2023.2173171","article-title":"Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: Focus on elderly patients","volume":"22","author":"Megna","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaad.2021.07.054","article-title":"COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence","volume":"85","author":"Wack","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1111\/jdv.17200","article-title":"Insights into SARS-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments","volume":"35","author":"Gisondi","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Skroza, N., Bernardini, N., Tolino, E., Proietti, I., Mambrin, A., Marchesiello, A., Marraffa, F., Rossi, G., Volpe, S., and Potenza, C. (2021). Safety and impact of anti-COVID-19 vaccines in psoriatic patients treated with bio-logics: A real life experience. J. Clin. Med., 10.","DOI":"10.3390\/jcm10153355"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","first-page":"11","article-title":"Safety and Efficacy of COVID-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis","volume":"13","author":"Potestio","year":"2023","journal-title":"Psoriasis (Auckl)"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"812010","DOI":"10.3389\/fmed.2021.812010","article-title":"Exacerbation of Psoriasis Following COVID-19 Vaccination: Report from a Single Center","volume":"8","author":"Huang","year":"2021","journal-title":"Front. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e857","DOI":"10.1111\/jdv.17582","article-title":"Psoriasis exacerbation after COVID-19 vaccination: A report of 14 cases from a single centre","volume":"35","author":"Sotiriou","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1111\/jdv.17965","article-title":"Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: Report of twelve cases from a single centre","volume":"36","author":"Koumaki","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/jdv.17665","article-title":"Reply to \u201cPsoriasis exacerbation after COVID-19 vaccination: Report of 14 cases from a single centre\u201d by Sotiriou E et al","volume":"36","author":"Megna","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e15331","DOI":"10.1111\/dth.15331","article-title":"Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID-19 vaccine: A report of three cases","volume":"35","author":"Durmaz","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e15464","DOI":"10.1111\/dth.15464","article-title":"Generalized erythrodermic psoriasis triggered by vaccination against severe acute res-piratory syndrome coronavirus 2","volume":"35","author":"Tran","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e15085","DOI":"10.1111\/dth.15085","article-title":"Onset\/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Ox-ford-AstraZeneca\/Covishield): Report of two cases","volume":"34","author":"Nagrani","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1111\/jdv.17918","article-title":"COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis","volume":"36","author":"Piccolo","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e15110","DOI":"10.1111\/dth.15110","article-title":"Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases","volume":"34","author":"Bostan","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1111\/jdv.18032","article-title":"Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab","volume":"36","author":"Pavia","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e15363","DOI":"10.1111\/dth.15363","article-title":"Erythroderma related with the first dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine in a patient with psoriasis","volume":"35","author":"Durmus","year":"2022","journal-title":"Dermatol Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1111\/1346-8138.16137","article-title":"Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine","volume":"48","author":"Fang","year":"2021","journal-title":"J Dermatol."},{"key":"ref_51","first-page":"e632","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdcr.2022.07.041","article-title":"Erythrodermic psoriasis after COVID-19 vaccination","volume":"28","author":"Trepanowski","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e15055","DOI":"10.1111\/dth.15055","article-title":"Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor","volume":"34","author":"Mieczkowska","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/08998280.2021.2003681","article-title":"Acute exacerbation of psoriasis after COVID-19 Pfizer vaccination","volume":"35","author":"Lopez","year":"2021","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2021.08.035","article-title":"Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine","volume":"17","author":"Perna","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_56","first-page":"e79","article-title":"Exacerbation of psoriasis following vaccination with the Pfizer-BioNTech BTN162b2 mRNA COVID-19 vaccine during risankizumab treatment","volume":"50","author":"Tsunoda","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1111\/jdv.18255","article-title":"Nail psoriasis: A rare mRNA COVID-19 vaccine reaction","volume":"36","author":"Lamberti","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e15590","DOI":"10.1111\/dth.15590","article-title":"New onset of psoriasis following COVID-19 vaccination","volume":"35","author":"Tran","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e15444","DOI":"10.1111\/dth.15444","article-title":"A case of new-onset acute generalized pustular psoriasis following Pfizer-BioNTech COVID-19 vaccine","volume":"35","author":"Frioui","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e15606","DOI":"10.1111\/dth.15606","article-title":"New-onset psoriasis after Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccine successfully treated with ixekizumab","volume":"35","author":"Cortonesi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.11.016","article-title":"New onset and exacerbation of psoriasis after COVID-19 vaccination","volume":"19","author":"Wei","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1111\/jdv.17561","article-title":"New onset of mainly guttate psoriasis after COVID-19 vaccination: A case report","volume":"35","author":"Lehmann","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ced.14895","article-title":"De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine","volume":"47","author":"Elamin","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_64","first-page":"e30","article-title":"De novo guttate psoriasis following coronavirus disease 2019 vaccination","volume":"49","author":"Song","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e15617","DOI":"10.1111\/dth.15617","article-title":"New-onset guttate psoriasis following coronavirus disease 2019 vaccination: About two cases","volume":"35","author":"Ouni","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1111\/jdv.18114","article-title":"De novo annular pustular psoriasis following mRNA COVID-19 vaccine","volume":"36","author":"Romagnuolo","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e15380","DOI":"10.1111\/dth.15380","article-title":"Erythrodermic psoriasis eruption associated with SARS-CoV-2 vaccination","volume":"35","author":"Nia","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_68","first-page":"e41","article-title":"Reply to \u2018Nail psoriasis: A rare mRNA COVID-19 vaccine reaction\u2019 by Lamberti A et al","volume":"37","author":"Lamberti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2021.09.009","article-title":"Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine","volume":"17","author":"Ricardo","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_70","first-page":"e80","article-title":"New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: Two sides of the same coin?","volume":"36","author":"Marcantonio","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e15030","DOI":"10.1111\/dth.15030","article-title":"Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?","volume":"34","author":"Megna","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Megna, M., Ocampo-Garza, S.S., Potestio, L., Fontanella, G., Gallo, L., Cacciapuoti, S., Ruggiero, A., and Fabbrocini, G. (2021). New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101482"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7774\/cevr.2023.12.1.80","article-title":"Psoriasis flares after COVID-19 vaccination: Adherence to biologic therapy reduces psoriasis exacerbations: A case-control study","volume":"12","author":"Burlando","year":"2023","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_74","unstructured":"Arnold, D.L., and Krishnamurthy, K. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1111\/jdv.17504","article-title":"New-onset cutaneous lichen planus triggered by COVID-19 vaccination","volume":"35","author":"Merhy","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","first-page":"e15422","article-title":"Lichen planus and vitiligo occurring after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2","volume":"35","author":"Gamonal","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_77","first-page":"e22669","article-title":"Lichen planus eruption following oxford-AstraZeneca COVID-19 vaccine administration: A case report and review of literature","volume":"14","author":"Alrawashdeh","year":"2022","journal-title":"Cureus"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e15651","DOI":"10.1111\/dth.15651","article-title":"Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases","volume":"35","author":"Shakoei","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1111\/jdv.17221","article-title":"Lichen planus arising after COVID-19 vaccination","volume":"35","author":"Hiltun","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e05092","DOI":"10.1002\/ccr3.5092","article-title":"Lichen planus flare following COVID-19 vaccination: A case report","volume":"9","author":"Herzum","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1111\/ajd.13902","article-title":"Linear lichen planus after COVID-19 vaccination","volume":"63","author":"Kato","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e15283","DOI":"10.1111\/dth.15283","article-title":"Lichen planus and lichen planopilaris flare after COVID-19 vaccination","volume":"35","author":"Diab","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e15374","DOI":"10.1111\/dth.15374","article-title":"New-onset lichen planus arising after COVID-19 vaccination","volume":"35","author":"Zagaria","year":"2022","journal-title":"Dermatol Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/jocd.14738","article-title":"Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine","volume":"21","author":"Awada","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s13555-022-00689-y","article-title":"A Case of New-Onset Lichen Planus after COVID-19 Vaccination","volume":"12","author":"Picone","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1111\/jocd.15185","article-title":"New-onset lichen planus and lichen planus flare in elderly women after COVID-19 vaccination","volume":"21","author":"Hlaca","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e15389","DOI":"10.1111\/dth.15389","article-title":"Lichen Ruber Planus occurring after SARS-CoV-2 vaccination","volume":"35","author":"Zengarini","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1111\/jdv.17899","article-title":"Extensive cutaneous lichen planus triggered by viral vector COVID-19 vaccination (ChAdOx1 nCoV-19)","volume":"36","author":"Masseran","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e15588","DOI":"10.1111\/dth.15588","article-title":"A 24-weeks real-world experience of dupilumab in adolescents with moder-ate-to-severe atopic dermatitis","volume":"35","author":"Napolitano","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e15120","DOI":"10.1111\/dth.15120","article-title":"Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis","volume":"34","author":"Napolitano","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40272-022-00531-0","article-title":"Dupilumab Treatment in Children Aged 6\u201311 Years With Atopic Dermatitis: A Multicentre, Real-Life Study","volume":"24","author":"Napolitano","year":"2022","journal-title":"Paediatr. Drugs."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Napolitano, M., Fabbrocini, G., Martora, F., Picone, V., Morelli, P., and Patruno, C. (2021). Role of Aryl Hydrocarbon Receptor Activation in Inflammatory Chronic Skin Diseases. Cells, 10.","DOI":"10.3390\/cells10123559"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e15346","DOI":"10.1111\/dth.15346","article-title":"Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report","volume":"35","author":"Cantelli","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/jdv.18137","article-title":"Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: A real-life experience","volume":"36","author":"Napolitano","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1111\/jdv.17761","article-title":"Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: A prospective cohort study in healthcare workers","volume":"36","author":"Rerknimitr","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdcr.2021.07.038","article-title":"A case series of cutaneous COVID-19 vaccine reactions at Loma Linda university de-partment of dermatology","volume":"16","author":"Holmes","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1111\/jdv.17494","article-title":"Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine","volume":"35","author":"Leasure","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.therap.2021.04.012","article-title":"Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine","volume":"76","author":"Bekkali","year":"2021","journal-title":"Therapie"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/cup.14104","article-title":"Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination","volume":"49","author":"Larson","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1111\/jdv.17964","article-title":"Atopic dermatitis exacerbation after COVID-19 vaccination in Dupilumab-treated patients","volume":"36","author":"Potestio","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/dermatopathology8040049","article-title":"Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines","volume":"8","author":"Niebel","year":"2021","journal-title":"Dermatopathology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.17744","article-title":"Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience","volume":"36","author":"Gambichler","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e15197","DOI":"10.1111\/dth.15197","article-title":"\u201cCOVID arm\u201d: Abnormal side effect after Moderna COVID-19 vaccine","volume":"35","author":"Picone","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jdcr.2021.02.014","article-title":"\u201cCOVID arm\u201d: A reaction to the Moderna vaccine","volume":"10","author":"Wei","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/ACI.0000000000000837","article-title":"Clinical phenotypes of adult atopic dermatitis and related therapies","volume":"22","author":"Patruno","year":"2022","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1111\/dth.13687","article-title":"Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during theCOVID-19 pandemic","volume":"33","author":"Ricardo","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_107","first-page":"249","article-title":"Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide","volume":"95","author":"Fan","year":"2022","journal-title":"Yale J. Biol. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1080\/09546634.2022.2102121","article-title":"Dupilumab for the treatment of adult atopic dermatitis in special populations","volume":"33","author":"Patruno","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000521712","article-title":"A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa?","volume":"8","author":"Martora","year":"2022","journal-title":"Ski. Appendage Disord."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ruggiero, A., Martora, F., Picone, V., Marano, L., Fabbrocini, G., and Marasca, C. (2022). Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020455"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis Suppurativa: Advances in Diagnosis and Treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2018.0814","article-title":"Diagnosis and Treatment of Hidradenitis Suppurativa","volume":"319","author":"Wortsman","year":"2018","journal-title":"JAMA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2022.05.005","article-title":"Response to Martora et al.\u2019s \u201cHidradenitis suppurativa flares following COVID-19 vaccination: A case series\u201d","volume":"25","author":"Alexander","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jdcr.2022.03.008","article-title":"Hidradenitis suppurativa flares following COVID-19 vaccination: A case series","volume":"23","author":"Martora","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CCID.S391356","article-title":"Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience","volume":"16","author":"Martora","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamadermatol.2021.4805","article-title":"Drug Survival of Biologics in Patients with Hidradenitis Suppurativa","volume":"158","author":"Ring","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/ced.15306","article-title":"Management of patients with hidradenitis suppurativa during COVID-19 vaccination: An experience from southern Italy. Comment on: \u2018Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_119","first-page":"e13875","article-title":"Management of patients with hidradenitis suppurativa during the COVID -19 pandemic","volume":"33","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e14256","DOI":"10.1111\/dth.14256","article-title":"Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy","volume":"33","author":"Molinelli","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/ced.15291","article-title":"Strategies adopted in a southern Italian referral centre to reduce adalimumab dis-continuation: Comment on \u2018Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Martora, F., Scalvenzi, M., Ruggiero, A., Potestio, L., Battista, T., and Megna, M. (2023). Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina, 59.","DOI":"10.3390\/medicina59040801"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2021.11.023","article-title":"Alopecia areata after SARS-CoV-2 vaccination","volume":"20","author":"Scollan","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000528719","article-title":"Alopecia Areata after COVID-19 Vaccines","volume":"9","author":"Genco","year":"2023","journal-title":"Ski. Appendage Disord."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jdcr.2022.08.016","article-title":"COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy","volume":"29","author":"Babadjouni","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1111\/jocd.14581","article-title":"Recurrence of alopecia areata after COVID-19 vaccination: A report of three cases in Italy","volume":"20","author":"Rossi","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e15689","DOI":"10.1111\/dth.15689","article-title":"Intractable alopecia areata following the second dose of COVID-19 vaccination: Report of two cases","volume":"35","author":"Chen","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_128","first-page":"e27953","article-title":"Alopecia areata universalis precipitated by SARS-CoV-2 vaccine: A case report and narrative review","volume":"14","author":"Abdalla","year":"2022","journal-title":"Cureus"},{"key":"ref_129","first-page":"e15677","article-title":"New-onset systemic lupus erythematosus after ChAdOX1 nCoV-19 and alopecia areata after BNT162b2 vaccination against SARS-CoV-2","volume":"35","author":"Gamonal","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2022.05.002","article-title":"Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)","volume":"25","author":"Ho","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.jfma.2022.03.006","article-title":"Alopecia areata following ChAdOx1 nCoV-19 vaccination (Oxford\/AstraZeneca)","volume":"121","author":"Su","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7774\/cevr.2022.11.1.129","article-title":"Alopecia areata after COVID-19 vaccination","volume":"11","author":"Gallo","year":"2022","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/ijd.16113","article-title":"Alopecia areata following COVID-19 vaccination: Vaccine-induced autoimmunity?","volume":"61","author":"Bertolani","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/jocd.14459","article-title":"Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford\/AstraZeneca): A potential triggering factor?","volume":"20","author":"Essam","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_135","first-page":"e7","article-title":"Alopecia areata after COVID-19 infection and vaccination: A cross-sectional analysis","volume":"37","author":"Nguyen","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1111\/ijd.16236","article-title":"Impact of the COVID-19 pandemic on hospital admissions of patients with rare dis-eases: An experience of a Southern Italy referral center","volume":"61","author":"Martora","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1111\/jdv.18302","article-title":"Reply to \u2018Development of severe pemphigus vulgaris following SARS-CoV-2 vac-cination with BNT162b2\u2032 by Solimani et\u2009al","volume":"36","author":"Martora","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2022.05.013","article-title":"Pemphigus vulgaris after COVID-19 infection and vaccination","volume":"87","author":"Zou","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jdcr.2022.07.002","article-title":"New-onset pemphigus vegetans and pemphigus foliaceus after SARS-CoV-2 vaccination: A report of 2 cases","volume":"27","author":"Gui","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e15827","DOI":"10.1111\/dth.15827","article-title":"Two cases with new onset of Pemphigus Foliaceus after SARS-CoV-2 vaccination","volume":"35","author":"Rouatbi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_141","first-page":"2324212","article-title":"Coexistence of pemphigus vulgaris and lichen planus following COVID-19 vac-cination","volume":"2022","author":"Aryanian","year":"2022","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1111\/odi.14089","article-title":"Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-CoV-2 vaccine","volume":"28","author":"Koutlas","year":"2021","journal-title":"Oral Dis."},{"key":"ref_143","first-page":"e251","article-title":"Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient","volume":"36","author":"Knechtl","year":"2022","journal-title":"J. Eur. Acad. Dermato.l Venereol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jdcr.2022.01.027","article-title":"Severe flare of pemphigus vulgaris after first dose of COVID-19 vaccine","volume":"22","author":"Ong","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_145","first-page":"e15381","article-title":"New onset of pemphigus foliaceus following BNT162b2 vaccine","volume":"35","author":"Demirkesen","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/jocd.14945","article-title":"Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vac-cination and review of literature","volume":"21","author":"Singh","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_147","first-page":"e74","article-title":"Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV-2 vaccination","volume":"50","author":"Norimatsu","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e15769","DOI":"10.1111\/dth.15769","article-title":"Pemphigus vulgaris following second dose of mRNA-(Pfizer-BioNTech) COVID-19 vaccine","volume":"35","author":"Agharbi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_149","first-page":"e1","article-title":"New onset pemphigus foliaceus following AstraZeneca COVID-19 vaccination","volume":"37","author":"Ayyalaraju","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_150","first-page":"229","article-title":"Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019","volume":"50","author":"Barei","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1111\/jdv.17480","article-title":"Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2","volume":"35","author":"Solimani","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jocd.15374","article-title":"Pemphigus vulgaris and COVID-19 vaccination: Management and treatment","volume":"22","author":"Martora","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"841506","DOI":"10.3389\/fmed.2022.841506","article-title":"Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study","volume":"9","author":"Maronese","year":"2022","journal-title":"Front. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e15496","DOI":"10.1111\/dth.15241","article-title":"Reply to \u201cNew-onset bullous pemphigoid after inactivated COVID-19 vaccine: Synergistic effect of the COVID-19 vaccine and vildagliptin\u201d","volume":"35","author":"Bostan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_155","first-page":"e23127","article-title":"Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases","volume":"14","author":"Hali","year":"2022","journal-title":"Cureus"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjd.20890","article-title":"Bullous pemphigoid after SARS-CoV-2 vaccination: Spike-protein-directed im-munofluorescence confocal microscopy and T-cell-receptor studies","volume":"186","author":"Gambichler","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_157","first-page":"e26383","article-title":"Dyshidrosiform Bullous Pemphigoid Triggered by COVID-19 Vaccination","volume":"14","author":"Shanshal","year":"2022","journal-title":"Cureus"},{"key":"ref_158","first-page":"e24126","article-title":"Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine","volume":"14","author":"Desai","year":"2022","journal-title":"Cureus"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jfma.2022.02.017","article-title":"A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination","volume":"121","author":"Fu","year":"2022","journal-title":"J. Formosan. Med. Assoc."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"103420","DOI":"10.1016\/j.amsu.2022.103420","article-title":"Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) COVID-19 vaccine: A case report","volume":"75","author":"Alshammari","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1111\/jdv.17955","article-title":"Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination","volume":"36","author":"Hung","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1111\/jdv.17891","article-title":"Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review","volume":"36","author":"Pauluzzi","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_163","first-page":"e15208","article-title":"Bullous pemphigoid triggered by COVID-19 vaccine: Rapid resolution with cortico-steroid therapy","volume":"35","author":"Anedda","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_164","first-page":"e333","article-title":"Bullous pemphigoid and COVID-19 vaccine","volume":"157","year":"2021","journal-title":"Med. Clin."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.annder.2021.07.008","article-title":"Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine","volume":"149","author":"Agharbi","year":"2022","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/jdv.17676","article-title":"A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine","volume":"36","author":"Young","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1111\/1346-8138.16170","article-title":"Case of bullous pemphigoid following coronavirus disease 2019 vaccination","volume":"48","author":"Nakamura","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/jdv.18503","article-title":"Bullous pemphigoid and COVID-19 vaccination: Management and treatment reply to \u2018Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review\u2019 by Pauluzzi et al","volume":"37","author":"Martora","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/jmv.27535","article-title":"Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies?","volume":"94","author":"Martora","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/jdv.12942","article-title":"Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: A review of the liter-ature","volume":"30","author":"Drago","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jdin.2022.03.018","article-title":"Pityriasis rosea and pityriasis rosea-like eruptions after COVID-19 vaccines","volume":"9","author":"Drago","year":"2022","journal-title":"JAAD Int."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.clindermatol.2022.01.002","article-title":"Pityriasis rosea, pityriasis rosea\u2013like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination","volume":"40","author":"Drago","year":"2022","journal-title":"Clin. Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1111\/jocd.14372","article-title":"Pityriasis rosea following SARS-CoV-2 vaccination: A case series","volume":"20","author":"Temiz","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_174","first-page":"1123","article-title":"Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2","volume":"20","author":"Ramot","year":"2022","journal-title":"J. Der Dtsch. Dermatol. Ges."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e15225","DOI":"10.1111\/dth.15225","article-title":"Pityriasis rosea after Moderna mRNA-1273 vaccine: A case series","volume":"35","author":"Martora","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_176","first-page":"003164","article-title":"Pityriasis Rosea Induced by COVID-19 Vaccination","volume":"9","author":"Khattab","year":"2022","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1111\/jdv.17342","article-title":"Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine","volume":"35","author":"Cyrenne","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"317","DOI":"10.12788\/cutis.0411","article-title":"Pityriasis rosea associated with COVID-19 vaccination: A common rash following administration of a novel vaccine","volume":"108","author":"Valk","year":"2021","journal-title":"Cutis."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jdin.2022.01.009","article-title":"Pityriasis rosea\u2013like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature","volume":"7","author":"Buckley","year":"2022","journal-title":"JAAD Int."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jfma.2021.12.028","article-title":"Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review","volume":"121","author":"Wang","year":"2022","journal-title":"J. Formosan. Med. Assoc."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijid.2021.10.055","article-title":"Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination","volume":"114","author":"Shin","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.27364","article-title":"Atypical pityriasis rosea associated with mRNA COVID-19 vaccine","volume":"94","author":"Bostan","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"752443","DOI":"10.3389\/fmed.2021.752443","article-title":"Case report: Pityriasis rosea-like Eruption following COVID-19 vac-cination","volume":"8","author":"Leerunyakul","year":"2021","journal-title":"Front. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1080\/21645515.2021.1963173","article-title":"Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine","volume":"17","author":"Cohen","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_185","first-page":"431","article-title":"Pityriasis Rosea as a Possible Complication of Vaccination Against COVID-19","volume":"118","author":"Dormann","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_186","first-page":"e27108","article-title":"Pityriasis rosea following pfizer-BioNTech vaccination in an adolescent girl","volume":"14","author":"Rubaian","year":"2022","journal-title":"Cureus"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/08998280.2022.2044742","article-title":"Inverse pityriasis rosea secondary to COVID-19 vaccination","volume":"35","author":"Fenner","year":"2022","journal-title":"Bayl. Univ. Med Cent. Proc."},{"key":"ref_188","first-page":"e721","article-title":"Pityriasis rosea developing after COVID-19 vaccination","volume":"35","author":"Cruz","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/ijd.15700","article-title":"Pityriasis rosea after mRNA COVID-19 vaccination","volume":"60","author":"Abdullah","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_190","first-page":"e34","article-title":"Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination","volume":"185","author":"Morgado","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e14972","DOI":"10.1111\/dth.14972","article-title":"Pityriasis rosea infection in a COVID-19 patient successfully treated with systemic steroid and antihistamine via telemedicine: Literature update of a possible prodromal symptom of an underlying SARS-CoV-2 infection","volume":"34","author":"Paolino","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e804","DOI":"10.1002\/iid3.804","article-title":"Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after COVID-19 vaccine: A systematic review","volume":"11","author":"Khan","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2500\/aap.2022.43.210111","article-title":"Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2","volume":"43","author":"Magen","year":"2022","journal-title":"Allergy Asthma Proc."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e863","DOI":"10.1111\/jdv.18341","article-title":"Reply to \u2018Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study\u2019 by Bawane J et\u2009al","volume":"36","author":"Potestio","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Riad, A., Pokorn\u00e1, A., Attia, S., Klugarov\u00e1, J., Ko\u0161\u010d\u00edk, M., and Klugar, M. (2021). Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Re-public. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071428"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2021.05.018","article-title":"Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vac-cination in a series of 6 patients","volume":"14","author":"Sidlow","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Peigottu, M.F., Ferreli, C., Atzori, M.G., and Atzori, L. (2021). Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series. Diseases, 9.","DOI":"10.3390\/diseases9030058"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","article-title":"Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study","volume":"86","author":"McMahon","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_199","first-page":"e425","article-title":"Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. \u201cCOVID-arm\u201d: A clinical and histological characterization","volume":"35","author":"Hammerle","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/all.14839","article-title":"Skin tests in urticaria\/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing","volume":"76","author":"Bianchi","year":"2021","journal-title":"Allergy"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1111\/jdv.17268","article-title":"Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: An Italian single-centre case series","volume":"35","author":"Corbeddu","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/DAD.0000000000002036","article-title":"Unique Case of Urticarial Skin Eruptions After COVID-19 Vaccination","volume":"44","author":"Baraldi","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"e15123","DOI":"10.1111\/dth.15123","article-title":"Cutaneous adverse effects and contraindications to COVID -19 vaccination; four cases and an illustrative review from an Asian country","volume":"34","author":"Choi","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/iid3.428","article-title":"Skin rashes after SARS-CoV-2 vaccine: Which relationship if any?","volume":"9","author":"Patruno","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7774\/cevr.2021.10.3.298","article-title":"Acute urticarial rash after COVID-19 vaccination containing Polysorbate 80","volume":"10","author":"Burlando","year":"2021","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_206","first-page":"e18102","article-title":"Chronic Spontaneous Urticaria After COVID-19 Vaccine","volume":"13","author":"Thomas","year":"2021","journal-title":"Cureus"},{"key":"ref_207","first-page":"255","article-title":"Cutaneous reactions following COVID-19 vaccination assessed by dermatologists: A single-institutional study in Germany","volume":"21","author":"Wang","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_208","first-page":"e25195","article-title":"Reactivation of Herpes Zoster Virus After COVID-19 Vaccination: Is There Any Association?","volume":"14","author":"Agrawal","year":"2022","journal-title":"Cureus"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/ijd.16116","article-title":"Herpes zoster reactivation after COVID-19 vaccination\u2014A retrospective case series of 22 patients","volume":"61","author":"Naoum","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_210","first-page":"284","article-title":"Herpes Zoster after mRNA COVID-19 vaccination: A case series","volume":"20","author":"Monastirli","year":"2022","journal-title":"Skinmed"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"SI90","DOI":"10.1093\/rheumatology\/keab345","article-title":"Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with auto-immune inflammatory rheumatic diseases: A case series","volume":"60","author":"Furer","year":"2021","journal-title":"Rheumatology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e845","DOI":"10.1111\/jdv.17576","article-title":"Herpes zoster after ChAdOx1 nCoV-19 vaccine: A case series","volume":"35","author":"Vastarella","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1111\/jocd.14470","article-title":"Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus?","volume":"20","author":"Palanivel","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.metop.2022.100171","article-title":"Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: A two-vaccine related event?","volume":"13","author":"Vallianou","year":"2022","journal-title":"Metab. Open"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"445","DOI":"10.25259\/IJDVL_819_2021","article-title":"Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination","volume":"88","author":"Jiang","year":"2022","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e15411","DOI":"10.1111\/dth.15411","article-title":"A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine","volume":"35","author":"Martora","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"e01563","DOI":"10.1016\/j.idcr.2022.e01563","article-title":"Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient","volume":"29","author":"Tanizaki","year":"2022","journal-title":"IDCases"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1111\/jdv.18249","article-title":"Generalized morphea after COVID-19 vaccines: A case series","volume":"36","author":"Paolino","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_219","first-page":"e15709","article-title":"Generalized morphea following the COVID vaccine: A series of two patients and a bibliographic review","volume":"35","author":"Estenaga","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/ced.15349","article-title":"Morphoea following COVID-19 vaccination","volume":"47","author":"Oh","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ijd.16062","article-title":"A case of morphea following the COVID-19 mRNA vaccine: On the basis of viral spike proteins","volume":"61","author":"Metin","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"e05667","DOI":"10.1002\/ccr3.5667","article-title":"Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection","volume":"10","author":"Aryanian","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/ced.15396","article-title":"Comment on \u2018Morphoea following COVID-19 vaccination\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e04865","DOI":"10.1002\/ccr3.4865","article-title":"New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination","volume":"9","author":"Kaminetsky","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_225","first-page":"e20902","article-title":"Vitiligo Possibly Triggered by COVID-19 Vaccination","volume":"14","author":"Militello","year":"2022","journal-title":"Cureus"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jdcr.2022.06.003","article-title":"Vitiligo of the arm after COVID-19 vaccination","volume":"28","author":"Singh","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/jdv.18513","article-title":"New-onset vitiligo after COVID-19 mRNA vaccination: A causal asso-ciation?","volume":"37","author":"Nicolaidou","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ad.2022.06.012","article-title":"Facial vitiligo after SARS-CoV-2 vaccination","volume":"113","author":"Mateo","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdcr.2022.02.021","article-title":"New-onset of vitiligo in a child following COVID-19 vaccination","volume":"22","author":"Bukhari","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/jocd.14843","article-title":"Newly-developed vitiligo following COVID-19 mRNA vaccine","volume":"21","author":"Sivaz","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"e15196","DOI":"10.1111\/dth.15196","article-title":"Sudden onset of vitiligo after COVID-19 vaccine","volume":"35","author":"Ciccarese","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_232","first-page":"e15502","article-title":"COVID-19 and autoimmune phenomena: Vitiligo after AstraZeneca vaccine","volume":"35","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e15280","DOI":"10.1111\/dth.15280","article-title":"Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine","volume":"35","author":"Okan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"e15434","DOI":"10.1111\/dth.15434","article-title":"Vitiligo worsened following the second dose of mRNA SARS-CoV-2 vaccine","volume":"35","author":"Caroppo","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"e15146","DOI":"10.1111\/dth.15146","article-title":"Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female","volume":"34","author":"Majid","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jdcr.2021.08.013","article-title":"Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine","volume":"16","author":"Agaronov","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Cantisani, C., Chello, C., Grieco, T., Ambrosio, L., Kiss, N., Tammaro, A., Tosti, G., Paolino, G., and Pellacani, G. (2022). Cutaneous Reactions to COVID-19 Vaccines in a Monocentric Study: A Case Series. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133811"},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Camargo Coronel, A., Jim\u00e9nez Balderas, F.J., Qui\u00f1ones Moya, H., Hern\u00e1ndez Zavala, M.R., Mandinabeitia Rodr\u00edguez, P., Hern\u00e1ndez V\u00e1zquez, J.R., Zamora Zarco, S., and Aguilar Castillo, S.D. (2022). Dermatomyositis post vaccine against SARS-CoV-2. BMC Rheumatol., 6.","DOI":"10.1186\/s41927-022-00250-6"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jocd.15477","article-title":"COVID-19 and cutaneous manifestations: A review of the published literature","volume":"22","author":"Martora","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"e15791","DOI":"10.1111\/dth.15791","article-title":"Pityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine","volume":"35","author":"Hlaca","year":"2022","journal-title":"Dermatol Ther."},{"key":"ref_241","first-page":"e141","article-title":"Reply to \u2018A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine\u2019","volume":"37","author":"Martora","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/ced.15286","article-title":"Video and telephone teledermatology consultations during COVID-19 in compar-ison: Patient satisfaction, doubts and concerns","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40249-021-00915-3","article-title":"Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1111\/jdv.18214","article-title":"Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concom-itant COVID-19 infection","volume":"36","author":"Gambichler","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/07853890.2022.2031274","article-title":"Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines","volume":"54","author":"Fernandes","year":"2022","journal-title":"Ann. Med."},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Villani, A., Potestio, L., Fabbrocini, G., Troncone, G., Malapelle, U., and Scalvenzi, M. (2022). The Treatment of Advanced Melanoma: Therapeutic Update. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126388"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s12325-022-02044-1","article-title":"New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma","volume":"39","author":"Villani","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14740338.2022.1993819","article-title":"Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma","volume":"21","author":"Villani","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Villani, A., Scalvenzi, M., Micali, G., Lacarrubba, F., Fornaro, L., Martora, F., and Potestio, L. (2023). Management of Advanced Invasive Melanoma: New Strategies. Adv. Ther.","DOI":"10.1007\/s12325-023-02555-5"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Ruggiero, A., Potestio, L., Martora, F., Villani, A., Comune, R., and Megna, M. (2023). Bimekizumab treatment in patients with moderate to severe plaque psoriasis: A drug safety evaluation. Expert Opin. Drug Saf.","DOI":"10.1080\/14740338.2023.2218086"},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Camela, E., Potestio, L., Fabbrocini, G., Pallotta, S., and Megna, M. (2023). The holistic approach to psoriasis patients with comorbidities: The role of investigational drugs. Expert Opin. Investig. Drugs.","DOI":"10.1080\/13543784.2023.2219387"},{"key":"ref_252","first-page":"e14101","article-title":"Melanoma and COVID-19: A narrative review focused on treatment","volume":"33","author":"Elmas","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/jdv.18545","article-title":"Effects of COVID-19 pandemic on malignant melanoma diagnosis","volume":"37","author":"Villani","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"e13430","DOI":"10.1111\/dth.13430","article-title":"Challenges of COVID-19 pandemic for dermatology","volume":"33","author":"Wollina","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Martora, F., Fabbrocini, G., Megna, M., Scalvenzi, M., Battista, T., Villani, A., and Potestio, L. (2023). Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?. Life, 13.","DOI":"10.3390\/life13041037"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","article-title":"New frontiers in personalized medicine in psoriasis","volume":"22","author":"Camela","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1111\/jocd.15331","article-title":"Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: What we should know?","volume":"21","author":"Potestio","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"e15838","DOI":"10.1111\/dth.15838","article-title":"Urticaria relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: A single-center experi-ence","volume":"35","author":"Picone","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1111\/ced.15395","article-title":"Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics","volume":"47","author":"Megna","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.abd.2022.09.004","article-title":"COVID-19 infection and vaccines: Potential triggers of Herpesviridae reactivation","volume":"98","author":"Ballano","year":"2023","journal-title":"An. Bras. de Dermatol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"222","DOI":"10.7774\/cevr.2022.11.2.222","article-title":"Epstein-Barr virus reactivation after COVID-19 vac-cination in a young immunocompetent man: A case report","volume":"11","author":"Herzum","year":"2022","journal-title":"Clin. Exp. Vaccine Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1423\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:59:08Z","timestamp":1760126348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":261,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["v15071423"],"URL":"https:\/\/doi.org\/10.3390\/v15071423","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]}}}